Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


May 22, 2015 1:17 PM ET

Biotechnology

Company Overview of Tocagen Inc.

Company Overview

Tocagen Inc. is a clinical-stage biopharmaceutical company that engages in the discovery, development, and commercialization of gene therapy products for the selective treatment of cancer. The company focuses on developing a treatment for high grade glioma, a type of brain cancer that includes glioblastoma multiforme and anaplastic astrocytomas. Its products include Toca 511 and Toca FC that allows selective targeting of cancer cells, as well as a selective, local, and systemic antitumor immune response without off-target toxicity; Toca Gamma that leverages the immune system to clear locally injected cancerous tumors, as well as to create an arsenal of targeted immune cells to kill more dist...

3030 Bunker Hill Street

Suite 230

San Diego, CA 92109

United States

Founded in 2007

Phone:

858-412-8400

Fax:

858-412-8499

Key Executives for Tocagen Inc.

Co-Founder, Chief Executive Officer, President and Director
Age: 61
Co-Founder and Executive Vice President of Research & Pharmaceutical Development
Age: 66
Co-Founder, Executive Vice President of Corporate Development and Director
Age: 63
Chief Financial Officer, Executive Vice President and Director
Age: 63
Head of Business Development and Product Manager
Compensation as of Fiscal Year 2014.

Tocagen Inc. Key Developments

Tocagen Inc. Appoints David R. Parkinson, M.D., to the Board of Directors

Tocagen Inc. announced that David R. Parkinson, M.D., a venture partner at New Enterprise Associates (NEA), has been appointed to the board of directors of Tocagen. Among other prior roles, Dr. Parkinson was vice president of oncology development at Amgen, vice president of global clinical oncology development at Novartis and senior vice president at Biogen Idec, leading oncology research and development. Dr. Parkinson presently serves on the board of directors of Threshold Pharmaceuticals and Cerulean Pharma Inc. and previously served on the board of directors of Facet Biotech, acquired by Abbott, and Ambit Biosciences Corporation, acquired by Daiichi Sankyo.

Tocagen to Present Updated Interim Results from Studies Evaluating Toca 511 & Toca FC at the American Association of Neurological Surgeons/Congress of Neurological Surgeons Section on Tumors

Tocagen Inc. announced updated interim results from ongoing investigational studies of Toca 511 in combination with Toca FC will be presented by two principal investigators at the 11th Biennial Satellite Symposium of the American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Tumors, to be held May 1-2, 2015, in Washington, D.C. Toca 511 & Toca FC is being investigated in four clinical trials in patients with recurrent high grade glioma, including glioblastoma. A pivotal Phase 2/3 study in patients with recurrent glioblastoma or anaplastic astrocytoma (the "Toca 5" study) is anticipated to initiate in 2015. The combination of Toca 511 & Toca FC is designed to break immune tolerance to the tumor using a combination of mechanisms. Toca 511, a retroviral replicating vector (RRV), delivers a prodrug-activating gene selectively to cancer cells. Then the prodrug-activating enzyme produced in the cancer cell is designed to activate orally administered Toca FC, an investigational extended-release formulation of 5-fluorocytosine (5-FC), into a powerful antimetabolite, 5FU, which kills the infected cancer cell and neighboring 5-FU sensitive tumor cells. Glioma cells and myeloid derived suppressor cells in the tumor are known to be sensitive to 5-FU. In animal models, the production of 5-FU locally kills dividing tumor cells during each 5-FC cycle, which leads to durable and selective anticancer immune responses. Data from ongoing clinical trials show encouraging evidence for increased survival compared to historical benchmarks, excellent safety, and evidence to support the proposed mechanism of action.

Tocagen Appoints Paul Schimmel to the Board of Directors

Tocagen Inc. announced that Paul Schimmel, Ph.D., Hahn professor of molecular biology and chemistry at The Scripps Research Institute, has been appointed to the board of directors. Dr. Schimmel co-founded Alnylam Pharmaceuticals and currently serves as a member of the company's board of directors.

Similar Private Companies By Industry

Company Name Region
Adlyfe Inc. United States
Thermalin Diabetes, LLC United States
Oricula Therapeutics LLC United States
Tendyne Medical, Inc. United States
PDS Biotechnology Corporation United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Tocagen Inc., please visit www.tocagen.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.